Sidewinder Targets Solid Tumors with Bispecific ADCs on Novartis-Backed Funding

Sidewinder Therapeutics, a US-based biopharmaceutical company, has raised $137 million in Series B financing, with which the company aims to advance its pipeline of bispecific antibody-drug conjugates (ADCs) for cancer, it announced on April 7, 2026.¹ This latest round of financing signals growing investor confidence in a precision-targeting approach to cancer treatment as competition intensifies across the ADC landscape.²

The financing was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from OrbiMed and several new investors. Sidewinder’s bispecific ADC pipeline includes a lead candidate expected to enter clinical development in 2027.

“We are pleased to receive the support of this … group of investors and their shared enthusiasm in advancing Sidewinder’s mission to develop next-generation bispecific ADCs for difficult to treat cancers,” said Eric Murphy, PhD, co-founder and CEO of Sidewinder Therapeutics, in a company press release.¹ “The ADC field is at an inflection point driven by technological breakthroughs enabling next-generation bispecific ADCs, and Sidewinder is eager to lead this wave of innovation and advance promising therapies for patients with cancer.”

Why are bispecific ADCs emerging as the next frontier in oncology?

Unlike first-generation ADCs, which typically rely on a single antigen target, Sidewinder’s approach focuses on bispecific antibodies engineered to bind tumor-specific receptor co-complexes. This approach pairs an oncogenic driver with an internalizing receptor. This design aims to improve both selectivity and intracellular drug delivery, two of the most persistent challenges in ADC development.³

The company’s platform targets receptor co-complexes that are highly expressed on solid tumors, enabling more precise binding and enhanced internalization. By improving how efficiently payloads are delivered into cancer cells, bispecific ADCs could address safety and efficacy trade-offs that have constrained earlier ADC designs, according to the company.¹

Sidewinder’s pipeline is focused on high-prevalence, difficult-to-treat solid tumors, including squamous cell carcinomas of the lung and head and neck, as well as gastrointestinal cancers such as colorectal cancer, representing areas in which targeted therapies have historically delivered mixed results.

How does Sidewinder’s strategy compare in a crowded ADC market?

Investment in ADCs has surged in recent years, with major biopharma players pursuing next-generation constructs that incorporate novel linkers, payloads, and targeting strategies.⁴ Sidewinder’s emphasis on bispecific targeting aligns with an industry shift toward more complex biologic designs intended to overcome resistance mechanisms and improve tumor specificity.

The company is also leveraging established manufacturing and conjugation technologies through a collaboration with Lonza for Synaffix’s platform, which enables site-specific linker-payload attachment. This site-specific attachment is an increasingly important factor in ensuring consistent pharmacokinetics and safety profiles, according to the company.

“Sidewinder’s novel bispecific ADC pipeline has the potential to address key hurdles limiting safety and efficacy for this class of therapeutics,” said Daniel Estes, PhD, general partner at Frazier Life Sciences, in the release.¹

What does this financing mean for ADC innovation and competition?

The scale and syndicate composition of the Series B round underscore continued investor interest in differentiated ADC platforms, particularly those aiming to move beyond incremental improvements. With the expansion of clinical ADC pipelines, competition is shifting toward technologies that can demonstrate clear advantages in patient selection, tumor targeting, and durability of response.^1,2

Sidewinder’s approach, which combines bispecific antibody engineering with optimized payload delivery, positions it within a growing cohort of companies attempting to redefine ADC design rather than refine existing models.² If successful in clinical testing, such platforms could help unlock broader applications across solid tumors, in which efficacy has been more variable than in hematologic malignancies.

With its first clinical candidate expected in 2027, Sidewinder now faces the critical transition from platform validation to clinical proof of concept, which is a step that can determine whether bispecific ADCs can deliver on their promise to reshape targeted oncology therapeutics.

References

1. Sidewinder Therapeutics. Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer. Published April 8, 2026. Accessed April 8, 2026. https://sidewinderbio.com/news/sidewinder-therapeutics-announces-137-million-series-b-financing-to-advance-precision-bispecific-adcs-into-clinical-development-for-cancer/
2. SCRIBD. Beacon ADC 2025 Landscape Review Full. Jan. 5, 2026. Accessed April 8, 2026. https://www.scribd.com/document/1016236106/Beacon-ADC-2025-Landscape-Review-Full
3. Zhou X, Han Y, Fang Y, et al. Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy. Med 2025;6(10):100849. doi: 10.1016/j.medj.2025.100849
4. BCC Research. Antibody-Drug Conjugates: Technologies and Global Markets. Market Research Report. September 2024. https://www.bccresearch.com/market-research/pharmaceuticals/antibody-drug-conjugates-markets-report.html?utm_source=PRPHM161C&utm_medium=referral&utm_campaign=prnewswire